Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Sied KebirChristina SchaubNina JunoldElke HattingenNiklas SchäferJoachim P SteinbachAstrid WeyerbrockPeter HauRoland GoldbrunnerNorbert GalldiksJohannes WellerFrederic MackTheophilos TzaridisOliver BährClemens SeidelUwe SchlegelFriederike Schmidt-GrafVeit RohdeChristian BorchersGhazaleh TabatabaiMathias HänelMichael SabelRüdiger GerlachDietmar KrexClaus BelkaHartmut VatterMartin ProescholdtMartin GlasUlrich HerrlingerPublished in: Journal of neuro-oncology (2019)
Baseline T1-hyperintense and diffusion-restricted lesions are not suitable to predict progression-free or overall survival of patients treated with bevacizumab/irinotecan or temozolomide.